**Supplemental Table 1.** A comparison of patient and liver injury characteristics in patients with suspected drug-induced liver injury (DILI). Data are shown for the whole study cohort and compared between patients adjudicated as having a non-DILI liver injury and those adjudicated as having DILI.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **All patients**  **N=551** | **Possible or unlikely DILI**  **( n=109)** | **Probable, very likely or definite DILI**  **( n=442)** | **P value** |
| Age (years) | 50 ± 18 | 53 ± 18.5 | 49 ± 17.8 | 0.04 |
| Male (%) | 45.6 | 52.3 | 43.9 | 0.11 |
| Body mass index (kg/m2) | 28.2 ± 7.1 | 28 ± 6.9 | 28.2 ± 7.1 | 0.9 |
| Race/ethnicity (%)  White  Black  Asian  Other | 79.6  13.3  2.5  4.7 | 76.9  14.8  1.9  6.5 | 80.3  12.9  2.7  4.41 | 0.6 |
| Hispanics (%) | 5.6 | 6.4 | 5.4 | 0.7 |
| Latency (days) | 163 ± 496 | 173 ± 493 | 160 ± 497 | 0.8 |
| Alanine aminotransferase (IU/L) | 725 ± 921 | 739 ± 1117 | 721 ± 867 | 0.3 |
| Alkaline Phosphatase (IU/L) | 286 ± 280 | 365 ± 469 | 267 ± 2.4 | 0.08 |
| Bilirubin (mg/dL) | 6.3 ± 5.8 | 6.1 ± 6.4 | 6.3 ± 5.7 | 0.3 |
| INR (at onset)  INR (at peak MELD) | 1.3 ± 0.8  1.7 ± 1.5 | 1.5 ± 0.8  2.1 ± 2.1 | 1.3 ± 0.8  1.6 ± 1.3 | <0.001  <0.001 |
| Creatinine (mg/dL) | 1.2 ± 0.5 | 1.3 ± 0.7 | 1.2 ± 0.5 | 0.8 |
| MELD | 15.1 ± 6.4 | 16.2 ± 7.9 | 14.8 ± 6.1 | 0.2 |
| Albumin (g/dL) | 3.5 ± 0.7 | 3.3 ± 0.8 | 3.6 ± 0.7 | 0.006 |
| R value | 11.2 ± 16.9 | 10.8 ± 19.5 | 11.3 ± 16.4 | 0.06 |
| Injury pattern (%)  Hepatocellular  Mixed  Cholestatic | 48.6  22.5  28.9 | 46.8  12.8  40.4 | 49.1  24.9  26 | 0.003 |
| Class of agents (most common) (%)  Antimicrobial  Antineoplastic  Cardiovascular  Herbal and dietary supplement  Neurologic | 45.2  6.2  9.3  16.5  7.4 | 45  1.8  15.6  13.8  9.2 | 46.6  7.2  7.7  17.2  7 | 0.96  0.036  0.01  0.4  0.4 |
| Number of implicated agents | 1.4±0.7 | 1.4±0.7 | 1.4±0.7 | 0.5 |
| Number of concomitant drugs | 7.8±7.5 | 9.3±8.9 | 7.4±7.1 | 0.019 |
| RUCAM score | 6.2±2.3 | 4.3±2.8 | 6.7±1.8 | <0.001 |

¶Values shown as mean ± standard deviation, or percentages.

**Abbreviations: CCI**, Charlson Comorbidity Index; **DILI**, drug-induced liver injury; **INR**, international normalized ratio; **MELD,** Model for End-stage Liver Disease; **RUCAM,** Roussel Uclaf Causality Assessment Method.